Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock
Portfolio Pulse from
Calidi Biotherapeutics Inc. has closed a public offering of 5 million shares at $0.85 each, raising approximately $4.25 million. The company is focused on developing targeted antitumor virotherapies.
January 10, 2025 | 9:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Calidi Biotherapeutics completed a public offering, raising $4.25 million by selling 5 million shares at $0.85 each. This capital infusion could support its ongoing development of antitumor virotherapies.
The successful closing of the public offering provides Calidi with additional capital, which is crucial for a clinical-stage biotech company. This financial boost can support their R&D efforts, potentially leading to positive developments in their pipeline. The stock price may see a positive impact due to the increased financial stability and potential for future growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100